stopping and restarting glp 1 Many adults stop GLP-1 therapy within a year with low restart rates, analysis finds lookaside.instagram.com/seo/google_widget/crawler/...

Build a winning GLP-1 pharma marketing strategy that balances demand, safety concerns, and differentiation in a competitive market.

Metabolic health is highly dependent on intestinal and hepatic handling of dietary and endogenous lipids and lipoproteins

On this episode of unPAUSED, @drsalaswhalen and I...

Try multiple flavors before committing to a favorite

Here we review evolving concepts of incretin action, focusing predominantly on GLP-1, from discovery, to clinical proof of concept, to therapeutic outcomes

Backed by strong clinical evidence, GLP-1s are winning over doctors and patients alike and are reshaping treatment paradigms across comorbid conditions